The largest pharmaceutical company in the world by market cap just made one of the biggest bets yet on AI-discovered drugs - and the target includes the same GLP-1 category that produced Mounjaro and Zepbound.
Eli Lilly announced Sunday it has signed a global licensing and research deal with Hong Kong-listed Insilico Medicine worth up to $2.75 billion. Insilico will receive $115 million upfront, with the remainder tied to development, regulatory, and commercial milestone payments plus tiered royalties on future sales. In return, Lilly receives exclusive worldwide rights to develop, manufacture, and commercialize preclinical oral drug candidates that Insilico's AI systems have discovered across selected disease areas.
The deal was first reported by the Financial Times, which noted that one of the licensed assets is a GLP-1 drug candidate for diabetes - placing it in the same drug class as Lilly's blockbuster Mounjaro and Zepbound franchises. Insilico's pipeline page was recently updated to show a GLP-1 candidate as out-licensed to an undisclosed partner.
What Insilico Medicine Actually Does
Founded by Alex Zhavoronkov, Insilico Medicine is one of the most advanced generative AI drug discovery companies operating today. The company uses large language models and generative AI tools to identify novel molecular candidates, predict biological targets, and design drug compounds - work that has historically taken years and hundreds of millions of dollars using conventional methods.
Insilico has developed at least 28 drugs using generative AI, with nearly half already in clinical trials. The company builds its AI capabilities in Canada and the Middle East while conducting early drug development in China, where Lilly CEO David Ricks attended a high-level forum earlier this month alongside the company's announcement of a $3 billion China investment plan over the next decade.
Zhavoronkov's framing of the deal was unusually candid. He told CNBC that in some areas of AI, Lilly is actually better than Insilico - and that no other company exceeds them. He credited one specific Lilly individual for bringing biology, chemistry, and automation under one roof. As part of the deal, Insilico will join Lilly's Gateway Labs biotech development community.
Why the Deal Structure Matters
The $2.75 billion figure represents the deal's ceiling, not its floor. The milestone-heavy structure limits Lilly's immediate balance sheet exposure while preserving strong commercial incentives for Insilico to deliver. Milestones trigger only if Insilico's models produce validated targets, successful preclinical results, or candidates that reach human trials. That is a reasonable risk distribution for a technology that is still proving itself at scale.
Andrew Adams, Lilly's group vice president of Molecule Discovery, called Insilico's AI-enabled discovery a powerful complement to Lilly's clinical development capabilities. His framing pointed toward what a Lilly executive described as the real ambition of the collaboration: finding more biology using AI - not just accelerating known pathways but surfacing biological mechanisms that conventional research methods would never identify.
The Bigger Picture for AI Drug Discovery
The Lilly-Insilico deal is the latest in a rapidly accelerating wave of Big Pharma investment in AI drug development. The FDA has signaled intentions to reduce animal testing requirements in favor of AI-based modeling. Pharmaceutical R&D costs have climbed for decades without a corresponding improvement in pipeline productivity. Large drugmakers have responded by acquiring AI-focused biotechs, building internal data science teams, and now signing partnerships of this scale.
For business leaders tracking where AI is generating measurable commercial value, drug discovery is one of the clearest examples. The combination of a verified GLP-1 candidate, a $115 million upfront payment, and milestone structures reaching $2.75 billion signals that Lilly is treating AI drug discovery not as an experiment but as a core component of its pipeline strategy. The question the industry is now racing to answer is whether AI-discovered drugs can not only reach clinical trials but actually win approval and deliver the commercial results that justify these billion-dollar bets.
